Adenocarcinoma in situ (one of the lesions formerly known as BAC), is a localized small ([less than or equal to] 3 cm) adenocarcinoma with growth restricted to neoplastic cells along preexisting alveolar structures (lepidic growth), lacking stromal, vascular, or pleural invasion.
Lesions that meet the criteria for adenocarcinoma in situ have formerly been classified as BAC according to the strict definition of the 1999 (2) and 2004 (3) WHO classifications and as type A and B adenocarcinoma according to the 1995 Noguchi classification.
For small ([less than or equal to] 3 cm), solitary adenocarcinomas with pure lepidic growth, we recommend the term adenocarcinoma in situ, which defines patients who should have 100% disease-specific survival if the lesion is completely resected (strong recommendation, moderate-quality evidence).
1%) involved minimally invasive adenocarcinoma cases that were misdiagnosed as adenocarcinoma in situ at frozen section.
More than one factor was present in most cases where there was difficulty distinguishing between benign processes, adenocarcinoma in situ, and minimally invasive adenocarcinoma.
Assessment of invasion in lung adenocarcinoma classification, including adenocarcinoma in situ and minimally invasive adenocarcinoma.
Mucinous adenocarcinoma in situ
has been recommended as the new term for noninvasive cancers with goblet cells, but, using this proposed classification, mucinous adenocarcinoma in situ
and mucinous minimally invasive adenocarcinoma are extremely rare.
Human papillomavirus detection and histologic findings in women referred for atypical glandular cells or adenocarcinoma in situ
in their Pap smears.
Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases.
Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix.